| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer | CEO | Director
2 companies
Traversa Sergio is a Chief Executive Officer at RLMD, with reported holdings spanning 2 companies. Recent filings cover 29 purchases and 24 sales. Those positions are worth an estimated $6.2M at current prices.
Our model assigns Traversa Sergio a middling insider score of 64/100, based on 18 past trades. Over a 12-month horizon, 53.8% of those trades were profitable, with an average 12-month return of +9.1%.
Traversa Sergio's largest disclosed position is in RLMD as Chief Executive Officer, worth about $6.1M. Net of sales, the recent Form 4 record there shows accumulation of 1,350,459 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 24, 2021 | RLMD Relmada Therapeutics, Inc. | CEO | Sale+OE | 10,000 | $34.24 | $342,392.06 | -10.1% | |
| Feb 11, 2021 | RLMD Relmada Therapeutics, Inc. | CEO | Sale+OE | 1,446 | $35.43 | $51,238.43 | -1.6% | |
| Feb 10, 2021 | RLMD Relmada Therapeutics, Inc. | CEO | Sale+OE | 11,206 | $35.17 | $394,084.66 | -11.2% | |
| Feb 3, 2021 | RLMD Relmada Therapeutics, Inc. | CEO | Sale+OE | 3,278 | $35.07 | $114,969.62 | -3.6% | |
| Jan 27, 2021 | RLMD Relmada Therapeutics, Inc. | CEO | Sale+OE | 10,000 | $32.39 | $323,914.41 | -11.7% | |
| Jan 26, 2021 | RLMD Relmada Therapeutics, Inc. | CEO | Sale+OE | 4,070 | $35.43 | $144,179.94 | -5.1% | |
| Apr 15, 2016 | ATNM Actinium Pharmaceuticals, Inc. | Director | Buy | 3,000 | $2.02 | $6,060.00 | New | |
| Dec 15, 2015 | RLMD Relmada Therapeutics, Inc. | Chief Executive Officer | Buy | 18,970 | $3.05 | $57,792.11 | +5.9% | |
| Dec 14, 2015 | RLMD Relmada Therapeutics, Inc. | Chief Executive Officer | Buy | 30 | $2.97 | $89.10 | - |